MTOR and skin squamous cell carcinoma: Additionally, emerging systemic treatments like cemiplimab and mTOR inhibitors show promise in advanced cSCC, while topical kinase inhibitors provide a novel, minimally systemic approach to treating both AK and cSCC, potentially reducing adverse effects of traditional therapies.